Market Overview

Oppenheimer Initiates Prothena With Outperform

Prothena Shares Initiated With Buy At UBS
Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results
After Hours Gainers / Losers (Seeking Alpha)

Analysts at Oppenheimer initiated coverage on shares of Prothena (NASDAQ: PRTA) with a Outperform rating.

The target price for Prothena is set to $40.

Prothena shares have dropped 1.50% over the past 52 weeks, while the S&P 500 index has surged 16.93% in the same period.

Prothena's shares fell 0.71% to close at $20.94 yesterday.

Latest Ratings for PRTA

May 2015UBSInitiates Coverage onBuy
May 2015Credit SuisseAssumesOutperform
Dec 2014CitigroupMaintainsBuy

View More Analyst Ratings for PRTA
View the Latest Analyst Ratings

Posted-In: OppenheimerInitiation Analyst Ratings


Related Articles (PRTA)

Around the Web, We're Loving...